8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 9, 2026·SEC
Material company update
Mar 20, 2026·SEC
AN2 Therapeutics, Inc.(ANTX)Earnings, Financials & Key Ratios
ANTX•NASDAQ
Price updated Jun 11, 2026
AboutAN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.Show more
- Revenue$0
- EBITDA-$38M
- Net Income-$35M+31.5%
- EPS (Diluted)-1.16+32.6%
- ROE-52.14%-4.9%
- ROIC-61.06%-26.5%
ANTX Key Insights
AN2 Therapeutics, Inc. (ANTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 97 (top 3%)
✗Weaknesses
- ✗Profits declining 20.9% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ANTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANTX Price & Volume
AN2 Therapeutics, Inc. (ANTX) stock price & volume — 10-year historical chart
Loading chart...
ANTX Growth Metrics
AN2 Therapeutics, Inc. (ANTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM23.81%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM27.15%
Return on Capital
10 Years-146.98%
5 Years-58.59%
3 Years-57.51%
Last Year-56.42%
ANTX Recent Earnings
AN2 Therapeutics, Inc. (ANTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 11, 2026EPS
$0.29
Est $0.23
-26.1%
Revenue
—
Q2 2026
Mar 17, 2026EPS
$0.29
Est $0.24
-20.8%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.31
Est $0.23
-34.8%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$0.21
Est $0.31
+32.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.29vs $0.23-26.1% | — |
| Q2 2026 | Mar 17, 2026 | $0.29vs $0.24-20.8% | — |
| Q4 2025 | Nov 12, 2025 | $0.31vs $0.23-34.8% | — |
| Q3 2025 | Aug 12, 2025 | $0.21vs $0.31+32.3% | — |
Based on last 12 quarters of dataView full earnings history →
ANTX Peer Comparison
AN2 Therapeutics, Inc. (ANTX) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 INSM | 20.96B | 96.72 | -15.09 | 66.73% | -144.44% | -130.11% | 1.04 | |
 SPRO | 156.33M | 2.70 | 18 | 24.27% | 27.82% | 35.58% | 0.05 | |
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 ENTA | 267.22M | 11.51 | -3.00 | -3.42% | -89.56% | -64.04% | 3.11 | |
 IDYA | 2.53B | 28.84 | -22.53 | 30.24% | -62.17% | -13.96% | 0.03 | |
 TARS | 2.69B | 62.61 | -39.38 | 146.71% | -9.02% | -14.19% | 0.27 | |
 NKTR | 1.16B | 59.21 | -6.09 | -43.89% | -284.18% | -87% | 1.66 | |
 CRL | 9.06B | 188.06 | -64.63 | -0.85% | -4.59% | -5.66% | 0.95 |
Compare ANTX vs Peers
AN2 Therapeutics, Inc. (ANTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANTX Income Statement
AN2 Therapeutics, Inc. (ANTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 77K | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | -77K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | 100% | - | - | - |
Operating Expenses | 31.07M | 7.28M | 21.57M | 42.19M | 69.64M | 54.55M | 38.11M | 37.12M |
OpEx % of Revenue | - | - | - | - | - | - | - | - |
Selling, General & Admin | 1.73M | 1.26M | 4.67M | 12.75M | 14.76M | 14.07M | 13.34M | 13.3M |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 29.33M | 6.02M | 16.91M | 29.51M | 54.87M | 40.49M | 24.77M | 23.82M |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -31.07M▲ 0% | -7.28M▲ 76.6% | -21.57M▼ 196.2% | -42.26M▼ 95.9% | -69.64M▼ 64.8% | -54.55M▲ 21.7% | -38.11M▲ 30.1% | -37.12M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | 76.55% | -196.18% | -95.89% | -64.77% | 21.66% | 30.14% | - |
EBITDA | 0 | 0 | -21.57M | -42.19M | 0 | 0 | -38.11M | -36.6M |
EBITDA Margin % | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | - | - | -95.54% | 100% | - | - | -165.78% |
D&A (Non-Cash Add-back) | 31.07M | 7.28M | 0 | 77K | 69.64M | 54.55M | 0 | 0 |
EBIT | -31.07M | -13.6M | -21.57M | -40.96M | -64.73M | -51.32M | -38.11M | -36.6M |
Net Interest Income | 0 | 3K | 69K | 837K | 0 | 5.47M | 2.93M | 2.57M |
Interest Income | 0 | 3K | 69K | 1.35M | 0 | 5.47M | 2.93M | 2.57M |
Interest Expense | 0 | 0 | 0 | 514K | 0 | 0 | 0 | 0 |
Other Income/Expense | -2.74M | -6.32M | 31K | 1.31M | 4.9M | 3.23M | 2.94M | 2.57M |
Pretax Income | -33.81M▲ 0% | -13.6M▲ 59.8% | -21.54M▼ 58.4% | -40.96M▼ 90.1% | -64.73M▼ 58.1% | -51.32M▲ 20.7% | -35.17M▲ 31.5% | -34.55M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -33.81M▲ 0% | -13.6M▲ 59.8% | -21.54M▼ 58.4% | -40.96M▼ 90.1% | -64.73M▼ 58.1% | -51.32M▲ 20.7% | -35.17M▲ 31.5% | -34.55M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - |
Net Income Growth % | - | 59.77% | -58.37% | -90.11% | -58.05% | 20.72% | 31.46% | 23.81% |
Net Income (Continuing) | -33.81M | -13.6M | -21.54M | -40.96M | -64.73M | -51.32M | -35.17M | -34.55M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.30▲ 0% | -0.78▼ 160.0% | -1.50▼ 92.3% | -2.79▼ 86.0% | -2.74▲ 1.8% | -1.72▲ 37.2% | -1.16▲ 32.6% | -1.01▲ 0% |
EPS Growth % | - | -160% | -92.31% | -86% | 1.79% | 37.23% | 32.56% | 27.15% |
EPS (Basic) | -0.30 | -0.78 | -1.50 | -2.79 | -2.74 | -1.72 | -1.16 | - |
Diluted Shares Outstanding | 18.74M | 18.74M | 18.74M | 15.34M | 23.6M | 29.83M | 30.22M | 34.06M |
Basic Shares Outstanding | 18.74M | 18.74M | 18.74M | 15.34M | 23.6M | 29.83M | 30.22M | 34.06M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
ANTX Balance Sheet
AN2 Therapeutics, Inc. (ANTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 5.7M | 4.23M | 60.11M | 98.62M | 110.51M | 86.26M | 59.94M | 87.49M |
Cash & Short-Term Investments | 5.6M | 4.07M | 58.55M | 96.06M | 107.3M | 83.62M | 58M | 85.29M |
Cash Only | 5.6M | 4.07M | 12.1M | 27.22M | 15.65M | 21.35M | 19.94M | 53.49M |
Short-Term Investments | 0 | 0 | 46.46M | 68.84M | 91.65M | 62.27M | 38.06M | 31.8M |
Accounts Receivable | 0 | 0 | 0 | 0 | 1.4M | 300K | 900K | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 82K | 0 | 0 | 2.56M | 0 | 2.34M | 1.04M | 2.2M |
Total Non-Current Assets | 0 | 0 | 5.21M | 3.94M | 28.24M | 5.83M | 2.01M | 0 |
Property, Plant & Equipment | 0 | 0 | 0 | 53K | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 3.49M | 3.22M | 27.19M | 5.02M | 2.01M | 13.53M |
Other Non-Current Assets | 0 | 0 | 1.72M | 667K | 1.04M | 804K | 0 | 0 |
Total Assets | 5.7M▲ 0% | 4.23M▼ 25.7% | 65.32M▲ 1442.7% | 102.56M▲ 57.0% | 138.74M▲ 35.3% | 92.09M▼ 33.6% | 61.95M▼ 32.7% | 87.49M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | -25.72% | 1442.65% | 57.02% | 35.28% | -33.63% | -32.73% | -86.45% |
Total Current Liabilities | 159K | 1.46M | 3.4M | 7.19M | 14.04M | 10.24M | 8.72M | 5.56M |
Accounts Payable | 51K | 132K | 1.06M | 2.12M | 2.68M | 3.32M | 3.02M | 2.62M |
Days Payables Outstanding | - | - | - | 10.06K | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 14K | 330K | 6K | 4.69M | 2.47M | 5.7M | 2.95M |
Current Ratio | 35.85x | 2.90x | 17.70x | 13.72x | 7.87x | 8.43x | 6.87x | 15.73x |
Quick Ratio | 35.85x | 2.90x | 17.70x | 13.72x | 7.87x | 8.43x | 6.87x | 15.73x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 728K | 24K | 13K | 2K | 0 | 0 | 170K | 170K |
Long-Term Debt | 728K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 24K | 13K | 2K | 0 | 0 | 170K | 170K |
Total Liabilities | 887K | 1.48M | 3.41M | 7.19M | 14.04M | 10.24M | 8.89M | 5.73M |
Total Debt | 728K | 0 | 0 | 53K | 0 | 0 | 0 | 0 |
Net Debt | -4.87M | -4.07M | -12.1M | -27.17M | -15.65M | -21.35M | -19.94M | -53.49M |
Debt / Equity | 0.15x | - | - | 0.00x | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 1.46x |
Interest Coverage | - | - | - | -79.68x | - | - | - | - |
Total Equity | 4.81M▲ 0% | 2.75M▼ 42.8% | 61.91M▲ 2150.4% | 95.37M▲ 54.1% | 124.7M▲ 30.8% | 81.85M▼ 34.4% | 53.06M▼ 35.2% | 81.76M▲ 0% |
Equity Growth % | - | -42.84% | 2150.38% | 54.05% | 30.75% | -34.36% | -35.17% | -84.82% |
Book Value per Share | 0.26 | 0.15 | 3.30 | 6.22 | 5.28 | 2.74 | 1.76 | 2.40 |
Total Shareholders' Equity | 4.81M | 2.75M | 61.91M | 95.37M | 124.7M | 81.85M | 53.06M | 81.76M |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -5.8M | -20.32M | -47.38M | -89.72M | -154.46M | -205.78M | -240.95M | -250.98M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -27K | -374K | 275K | 31K | 57K | -5K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ANTX Cash Flow Statement
AN2 Therapeutics, Inc. (ANTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -2.49M | -5.36M | -20.48M | -33.46M | -53.29M | -49.26M | -29.83M | -31.28M |
Operating CF Margin % | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -115.77% | -281.88% | -63.36% | -59.25% | 7.56% | 39.43% | 81.14% |
Net Income | -5.63M | -13.6M | -21.54M | -40.96M | -64.73M | -51.32M | -35.17M | -34.55M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 0 | 40K | 974K | 4.39M | 8.41M | 8.34M | 6.25M | 4.2M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 3.16M | 6.97M | 53K | -615K | -2.8M | -3.28M | -1.07M | 752K |
Working Capital Changes | -10K | 1.22M | 32K | 3.72M | 5.83M | -3M | 164K | -1.68M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -16K | 81K | 417K | 2.5M | 553K | 641K | -296K | -457K |
Cash from Investing | 0 | 0 | -50.02M | -21.77M | -43.28M | 54.59M | 28.31M | 27.41M |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 8.08M | 3.84M | 78.53M | 70.36M | 84.99M | 372K | 113K | 37.38M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 8.08M | 3.77M | 79.73M | 70.37M | 84.53M | 372K | 113K | 37.38M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 64K | -1.2M | -11K | 465K | 0 | 0 | 0 |
Net Change in Cash | 5.6M▲ 0% | -1.53M▼ 127.3% | 8.03M▲ 625.3% | 15.12M▲ 88.4% | -11.57M▼ 176.5% | 5.7M▲ 149.3% | -1.41M▼ 124.7% | 33.5M▲ 0% |
Free Cash Flow | -2.49M▲ 0% | -5.36M▼ 115.8% | -20.48M▼ 281.9% | -33.46M▼ 63.4% | -53.29M▼ 59.2% | -49.26M▲ 7.6% | -29.83M▲ 39.4% | -31.28M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - |
FCF Growth % | - | -115.77% | -281.88% | -63.36% | -59.25% | 7.56% | 39.43% | 26.02% |
FCF per Share | -0.13 | -0.29 | -1.09 | -2.18 | -2.26 | -1.65 | -0.99 | -0.92 |
FCF Conversion (FCF/Net Income) | 0.07x | 0.39x | 0.95x | 0.82x | 0.82x | 0.96x | 0.85x | 0.91x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ANTX Key Ratios
AN2 Therapeutics, Inc. (ANTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -359.68% | -66.64% | -52.08% | -58.83% | -49.69% | -52.14% | -52.35% |
| Return on Invested Capital (ROIC) | - | -66.73% | -53.72% | -58.93% | -48.26% | -61.06% | -72.14% |
| Debt / Equity | - | - | 0.00x | - | - | - | 0.00x |
| Interest Coverage | - | - | -79.68x | - | - | - | - |
| FCF Conversion | 0.39x | 0.95x | 0.82x | 0.82x | 0.96x | 0.85x | 0.91x |
Related:ANTX Dividend History·ANTX Revenue History·ANTX Price History·ANTX P/E History·ANTX Financial Ratios·ANTX Institutional Holders
ANTX SEC Filings & Documents
AN2 Therapeutics, Inc. (ANTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
ANTX Frequently Asked Questions
AN2 Therapeutics, Inc. (ANTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
AN2 Therapeutics, Inc. (ANTX) grew revenue by 0.0% over the past year. Growth has been modest.
AN2 Therapeutics, Inc. (ANTX) reported a net loss of $34.6M for fiscal year 2025.
Dividend & Returns
AN2 Therapeutics, Inc. (ANTX) has a return on equity (ROE) of -52.1%. Negative ROE indicates the company is unprofitable.
AN2 Therapeutics, Inc. (ANTX) had negative free cash flow of $31.3M in fiscal year 2025, likely due to heavy capital investments.